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Staphylococcus (S.) aureus silently stays as our natural ﬂora, and yet sometimes threatens our life as a
tenacious pathogen. In addition to its ability to outwit our immune system, its multi-drug resistance
phenotype makes it one of the most intractable pathogenic bacteria in the history of antibiotic
chemotherapy. It conquered practically all the antibiotics that have been developed since 1940s. In 1961,
the ﬁrst MRSAwas found among S. aureus clinical isolates. Then MRSA prevailed throughout the world as
a multi-resistant hospital pathogen. In 1997, MRSA strain Mu50 with reduced susceptibility to vanco-
mycin was isolated. Vancomycin-intermediate S. aureus (VISA), so named according to the CLSI criteria,
was the product of adaptive mutation of S. aureus against vancomycin that had long been the last resort
to MRSA infection. Here, we describe the genetic basis for the remarkable ability of S. aureus to acquire
multi-antibiotic resistance, and propose a novel paradigm for future chemotherapy against the multi-
resistant pathogens.
© 2014, Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases.
Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Among all the antibiotic resistance achieved by Staphylococcus
aureus, two most remarkable ones are methicillin and vancomycin
resistance. The methicillin resistance was achieved by interspecies
transfer of mecA gene from an ancestral Staphylococcus species to
S. aureus mediated by a unique staphylococcal mobile genetic
element. Vancomycin resistance was achieved by horizontal
transfer of a plasmid-born vanA-gene transposon from
vancomycin-resistant Enteriococcus to S. aureus across the genus
barrier. The other type of vancomycin resistance is expressed by
VISA, which is acquired by adaptive mutations incorporated in the
genes encoding regulation of bacterial cell physiology. We shall
describe below the genetic strategies underlying the organism's
admirable adaptability to antimicrobial pressures, and propose the
development of ‘reverse antibiotics (RA)’ as a new paradigm forylococcus (S.) aureus; PBP,
ediate S. aureus; hVISA, het-
SA, slow VISA; VRSA, vanco-
ette chromosome mec; TCRS,
iotic; RNAP, RNA polymerase.
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d The Japanese Association for Infectidrug discovery development in the future chemotherapy against
the threat of multi-resistant S. aureus infection.2. Great genetic competence of S. aureus to acquire antibiotic
resistance
2.1. Methicillin resistance in S. aureus
Practically all S. aureus isolatesweremethicillin susceptible until
1961, when Jevons found three MRSA strains among 5440 clinical
S. aureus strains in England [61]. Then the situation changed as
humans started to use methicillin. MRSA became prevalent all over
theworld, and after ﬁve decades, more than half of S. aureus clinical
strains became methicillin resistant. MRSA is born when
methicillin-susceptible S. aureus (MSSA) has acquired the
methicillin-resistance gene mecA by horizontal gene transfer
mediated by a mobile genetic element staphylococcal cassette
chromosome (SCC) [2]. SCC is a site-speciﬁc transposon-like
element exclusively used among staphylococcal species [3]. The
SCC elements carrying mecA, designated SCCmec, are integrated in
the chromosomes of MRSA strains [2,4]. Fig. 1 illustrates the basic
structure of SCCmec [5]. The element is composed of mec-gene
complex encoding methicillin resistance gene mecA, and its regu-
lator genes (mecR1 and mecI) and ccr-gene complex encoding
cassette chromosome recombinase (CCR) that mediates theous Diseases. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.
Fig. 1. The structure of SCCmec. SCCmec is composed of two essential gene complexes.
One is mec-gene complex, encoding methicillin resistance (mecA gene) and its regu-
lators (mecI and mecR1), and the other is ccr-gene complex that encodes the move-
ment, (integration to and precise excision form the chromosome), of the entire SCC
element. Abbreviations: IR, inverted repeat; DR, direct repeat.
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staphylococcal chromosome [3]. There are many structurally
distinguishable types and subtypes in SCCmec. Detailed description
is available elsewhere [5].
1) oriC environ as the storage system for useful exogenous genes
SCC is a vehicle for staphylococcal species to exchange genes
that are useful for their adaptation to the niches with adverse
environmental condition including antibiotic pressure. In the
S. aureus chromosomal region downstream of the origin of repli-
cation (oriC), a gene named orfX is present. The gene is reported to
encode a ribosomal RNA methyltransferase [6]. The orfX contains a
copy of the direct repeat sequences (DR) that bracket an SCC
element (Fig. 1), thus it serves as the unique integration site for SCC
elements. Moreover, after the ﬁrst SCC element is integrated, the
second SCC can be integrated at the DR sequence present in the
distal side of the ﬁrst SCC element. In this way, multiple elements
can be integrated in tandem forming a cluster of foreign genes
downstream of orfX. As a result, unique chromosomal region called
‘oriC environ’ is formed [5,7].
The oriC environ is the most diverged region among Staphylo-
coccus chromosomes in terms of its length, GC content, and func-
tion of the acquired genes and their integrity. Many transposons
and insertion sequences (IS) are found in the oriC environ, and they
frequently cause deletion, recombination and even a large chro-
mosome inversion across oriC [7]. In this way staphylococci can
maintain only the genes needed for the survival in the on-going
environmental change. Evidently, mecA has been the most useful
gene ever since the clinical introduction of methicillin in 1960,
when a few S. aureus strains already seem to have acquired mecA
[1].
Various functional genes of diverse metabolic pathways are
found carried by SCC in the staphylococcal oriC environ. Some ex-
amples are; pbp4, encoding penicillin-binding protein 4 (PBP4) in
the cell-wall synthesis pathway [8], arginine catabolic pathway
genes (ACME) [9], and hdc encoding histidine decarboxylase [10].
However, the genes much more frequently found in the oriC envi-
ron are drug-resistance genes. Besides mecA, such drug-resistance
genes against mercury, cadmium, kanamycin, bleomycin, erythro-
mycin, spectinomycin, and fusidic acid have been found in associ-
ation with SCC elements in oriC environ [4,11]. Evidently, the oriC
environ serves as the storehouse in support for achieving themulti-
drug-resistance phenotype. S. aureus quickly acquired b-lactamase
plasmids soon after the penicillin Gwas introduced in 1940s, but no
plasmid carrying mecA has been found. Although the reason is not
clear, SCC-mediated acquisition of a single copy ofmecA gene on the
chromosome might have been less effective against penicillin-G as
compared to the plasmid-born multiple copies of beta-lactamase
encoding blaZ genes. On the other hand, mecA encodes cell-wallsynthesis enzyme PBP2’ [12]. PBP2’ is a homolog of intrinsic
S. aureus PBPs and considered to have inefﬁcient transpeptidase
activity [13,14]. As such, overproduction of PBP2’ may cause tur-
bulence in the cell-wall synthesis and a big ﬁtness cost especially
during the growth in the absence of b-lactam antibiotics. Storage of
mecA as a single gene copy in oriC environ and multiple gene doses
of blaI on the penicillinase plasmid would be the best way to
maintain mecA in the repressed status in the drug-free growth
condition. (Here, note that blaI gene is the cognate repressor gene
of blaZ. The BlaI also cross-represses mecA gene because the
cognate mecA-gene repressor gene mecI is usually deleted or
inactivated by mutations [15].) Apparently, oriC environ is suitable
for the storage of foreign genes in single copies that may have a
hazardous effect on the cell physiology if overexpressed.
2) The origin of mecA gene
We previously identiﬁed a mecA-gene homolog mecB on the
plasmids and chromosomes of Macrococcus caseolyticus isolates
[16,17]. Macrococcal species, disseminated in nature as animal
commensals, are immediate antecedents of staphylococcal species
(Fig. 2) [17]. The macrococcal mecB was distantly related to mecA
(61.7% nucleotide identity), andwas found disseminated among the
macrococcal strains as a transposon, designated Tn6045 [16]. No
complete form of SCCmec was found in macrococcal strains. How-
ever, many ccr genes are found on the plasmids and chromosomes
of the macrococci, and tandem integration of an SCC element and a
mecB transposonwas observed in the oriC environ of a macrococcal
strain [16]. Spontaneous excision of an SCC and the mecB trans-
poson as a closed circle DNA from the oriC environ was observed,
suggesting de novo synthesis of SCCmec is on-going in macrococcal
species [16].
Recently, the third mecA gene homolog mecC, which exhibits
68.7% nucleotide identity withmecA, was found in S. aureus isolates
from cattle and a human by using next generation sequencing
technology [18]. The SCCs carrying mecC were also found in
Staphylococcus sciuri [19], and Staphylococcus xylosus [20]. Previ-
ously, mecA was the exclusive genetic marker for MRSA. Now,
however, we have to worry about overlooking mecB or mecC-car-
rying MRSA in the clinical laboratory. According to recent reports,
prevalence of mecC-mediated methicillin resistance ranges from
0 to 2.8% among human MRSA isolates [21e25]. There is no report
yet of mecB-carrying S. aureus.
Phylogenetic distribution of the mecA homologs illustrated in
Fig. 2 suggests that mecA had been vertically transmitted as an
ortholog for some time during the course of speciation of sciuri-
group staphylococcal species such as Staphylococcus ﬂeurettii,
Staphylococcus vitulinus, S. sciuri subspecies sciuri, and Staphylo-
coccus carnaticus. As the vertically transmitted ortholog, mecA,
mecA1, and mecA2 are located at the corresponding loci on the
chromosomes of the sciuri-group species; S. ﬂeurettii, S. sciuri, and
S. vitulinus, respectively. They have 99.8%, 80%, and 91% nucleotide
identities, respectively, to the mecA gene carried by SCCmec on the
MRSA chromosome [26]. Thus, apparently, S. ﬂeurettii mecAwas the
original mecA, which was adopted as the methicillin-resistance
determinant of the SCCmec that converted S. aureus into MRSA.
The comparative structural analysis of the mecA loci on the chro-
mosomes of sciuri-group species corroborated this historical event
[26]. Curiously, however, themecA locus was not preserved intact in
certain strains of sciuri group. Some of them possessed SCCmec
elements carrying either mecA or mecC in the oriC environ instead
of the functionalmecA ortholog (Fig. 2) [27]. They seem to have had
lost methicillin resistance by either deletion or mutations incor-
porated in the coding region or promoter sequence of the original
mecA gene [28].
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Fig. 2. Phylogenetic tree of mecA gene homologs. Nucleotide sequences were obtained from the NCBI database and our ongoing project. The multiple codon alignment was
performed using pal2nal v14 from the corresponding aligned protein sequences by MAFFT v7.037. Maximum likelihood tree was built with MEGA5 using a GTR þ Gamma model.
The numbers at branches are bootstrap values indicating the conﬁdence levels. The scale bar indicates an expected value of base substitution per site.
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been identiﬁed only for mecA gene. In view of the distribution of
mecC and mecB genes (Fig. 2), however, it seems likely that they
were derived from the bacteria of the taxonomic positions between
contemporary genera Staphylococcus and Macrococcus, although it
is not clear if the bacterial species are still existent or already
extinct.
3) Co-evolution of staphylococci and mammals and loss of mecA
Some staphylococcal species exhibit evident host-speciﬁc
colonization. For example, Staphylococcus epidermidis is a member
of human microﬂora, and Staphylococcus pseudintermedius is iso-
lated speciﬁcally from canine hosts [29,30]. In our ongoing
ecological study of staphylococci inmammalian species, we found a
co-evolutionary relationship between Staphylococcus delphini-
group (Staphylococcus hyicus, Staphylococcus chromogenes, Staphy-
lococcus felis, Staphylococcus lutrae, Staphylococcus schleiferi,
S. delphini, Staphylococcus intermedius and S. pseudintermedius) and
Laurasiatherian hosts after diverging from Chiropter (bats). Based
on this observation, the appearance of genus Staphylococcus was
estimated to be about 250 million years ago by molecular clock
method using genome-wide datasets (Fig. 3). Then, the staphylo-
coccal species seem to have started to colonize and co-evolve with
mammals that emerged almost simultaneously about 225 million
years ago (Fig. 3). It is probable that the antecedents of staphylo-
cocci, e.g. macrococcal species and old staphylococcal species of
S. sciuri-group required the beneﬁt ofmecA or mecC genes to protect
themselves from b-lactam-producing environmental microorgan-
isms before their descendants successfully adapted to mammalian
hosts. The descendant staphylococcal species, after successful
adaptation as mammalian microbial ﬂora, lost mecA or mecC gene,
because they became protected from the assault of b-lactam-pro-
ducing microorganisms thanks to the host's immune system. The
situation changed, however, in the 1940s, when humans started touse penicillin G, threatening the colonizing staphylococci. They ﬁrst
acquired penicillinase plasmid. Then, since the introduction of
methicillin in 1960, S. aureus had to regain mecA gene from
S. ﬂeurettii via the SCCmec.
2.2. Vancomycin resistance in S. aureus
1) hVISA, and VISA
Some important antibiotic resistance phenotypes of MRSA are
acquired by spontaneous mutations. Rifampin resistance and ﬂu-
oroquinolone resistance are the most well known examples.
Moreover, vancomycin resistance, which has cast a dark shadow on
anti-MRSA chemotherapy in the last two decades, is also acquired
by mutation. Vancomycin has long been regarded as the last resort
for MRSA infection. In 1997, however, the ﬁrst VISA strain Mu50
was isolated from the surgical wound of a Japanese infant whose
infection did not respond favorably to long-term vancomycin
therapy [31,32]. The vancomycin MIC of Mu50 was 8 mg/L [31].
Now VISA is deﬁned as S. aureus strain having vancomycin MIC
of 4 or 8 mg/L. Note that MIC  2 mg/L is deﬁned as susceptible.
However, among the susceptible clinical strains, there are precursor
strains for VISA. From the precursor strains, one-step selectionwith
vancomycin generates VISA at a frequency of 106 or above [52].
MIC determination cannot detect such precursor strains. Using
1000 times ormore number of cells (or colony forming unit; CFU) of
a bacterial strain than used for MIC method (about 104e5 CFU for
the test) we can discriminate the precursor strains from really
vancomycin-susceptible S. aureus (VSSA). This sensitive method is
called analysis of resistant subpopulation (population analysis
(PA)), and is an essential tool for the study of vancomycin and
methicillin resistance [72].
Fig. 4 illustrates the PA patterns of the MRSA strains with
different types of vancomycin susceptibility. A ﬁxed number of cells
were inoculated on each of the agar plates containing various
Fig. 3. Comparison of phylogenetic time trees of staphylococci and mammalians. Each cluster was compressed as a colored triangle, whose thickness is proportional to the number
of species. Tree topology was constructed by maximum likelihood method using RAxML. Time estimation was performed by bayesian inference using MCMCTREE program included
in PAML 4.7 package. Amino acid sequences of 31 staphylococcal core genes were used for the construction of staphylococcal tree. Mammalian time tree was originated from a
report by Meredith RW et al. [62].
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at 37 C for 48 h. Then the number of grown colonies were counted
and plotted on the semi-logarithmic graph. Note that the precursor
strain Mu3 with MIC 2 mg/L is distinct from VSSA strain DIP (MIC
1 mg/L). Whereas the growth of DIP is completely depressed by
2 mg/L of vancomycin, the minor proportions of cells of Mu3 grewFig. 4. Population analysis of VSSA, hVISA, VISA and sVISA. The population analysis (PA) wa
The grown colonies were counted and plotted on the graph after 48 h, (which is the regular
Mu3 (red lines) generates new colonies on the vancomycin agar plates after 72 h incubation
line). These late-appearaing colonies of Mu3 contained sVISA strains. Mu3-6R-P (orange line
In contrast, the two PA curves of extant VISA strain Mu50 (light blue lines) were not that diff
circle, that determined after 144 h incubation. (For interpretation of the references to coloup to 12 mg/L of vancomycin though the 99.999% of the entire cell
population is depressed with 3 mg/L of vancomycin. This clearly
showed that Mu3 is composed of heterogeneous cell sub-
populations with different levels of vancomycin resistance. Within
the subpopulations grown on the agar plates containing 4 mg/L or
greater concentrations of vancomycin, we identiﬁed VISAs performed with BHI agar plates containing varied concentrations of vancomycin [72]
practice in PA method), and 144 h of incubation at 37 C. It is noticed that hVISA strain
up to 144 h, which was in contrast to the case for VSSA strain N315DIP (DIP) (dark green
s) was one of them. Its PA curve is drastically changed when analyzed at 48 h and 144 h.
erent each other. Symbols: cross, number of colonies determined after 48 h incubation;
ur in this ﬁgure legend, the reader is referred to the web version of this article.)
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a heterogeneously vancomycin-resistant S. aureus (hVRSA; now is
called hVISA) [52].
VISA is generated by accumulation of several spontaneous mu-
tations [33,34]. The VISA phenotype of Mu50, for instance, can be
reconstituted in VSSA strain DIP by sequentially introducing four
mutations in the genes vraS, msrR, rpoB and graR (Katayama, Y. in
preparation). The ﬁrst couple of two mutations in vraS and msrR
converted DIP into a hVISA strain with a similar PA pattern with
that of Mu3, then rpoB mutation converted the hVISA into VISA
with vancomycin MIC 4 mg/L. Addition of graR mutation further
increased vancomycin MIC to 8 mg/L.
vraS is the sensor histidine kinase of two-component regulatory
systems (TCRS), which is known to up-regulate the genes in the
cell-wall synthesis pathway in response to the exposure to cell-
wall-acting antibiotics [35,36]. graR is a response regulator of
another TCRS which is involved in resistance to cationic antimi-
crobial peptides (CAMP) [37e39].msrR is considered to be involved
in the production of wall-teichoic acid (WTA) [40,41]. The RNA
polymerase (RNAP) core enzyme is composed of ﬁve subunits as
represented by a2bb0u. Remarkably, as many as 64% of VISA clinical
strains possessed more than one mutation in rpoB gene encoding
the b subunit of the RNAP core enzyme [42].
When introduced individually into vancomycin-susceptible
S. aureus strain DIP, the above four mutations either increased
vancomycin MIC slightly, (i.e, within the susceptible range), or
changed the susceptible patterns of PA curves to those of hVISA.
Besides the four genes described above, great number of different
mutations and their combinations were found to raise vancomycin
resistance of S. aureus. A single mutation incorporated in any of the
20 genes in diverse metabolic pathways was found to raise van-
comycin resistance [33]. They are such genes as tarO and tarA, in the
WTA synthesis pathway; gtaB in the lipoteichoic acid biosynthesis
pathway; walk involved in the regulation of cell-wall synthesis and
autolysis; cmk responsible for the synthesis of cytidylate diphos-
phate (CDP); pykA, involved in both glycolysis and purine synthesis
pathways; rpsU, encoding small subunit ribosomal protein S21;
trpC in Tryptophan biosynthesis pathway, and ureD encoding ure-
ase accessory protein [33].
Alteration of such a diverse metabolic pathway genes seems to
change the ﬂowof nutrients andmetabolites towards the enhanced
production of cell-wall peptidoglycan (PG) and/or reduction in
autolysis [42]. Besides supporting the cell to tolerate the cytokilling
activity of vancomycin, reduced autolysis is considered to
contribute to the maintenance of thick cell-wall PG layers by
decreasing the rate of cell-wall turnover. In fact, considerable
number of mutations affecting the above 20 genes are speculated to
contribute to the enhanced cell-wall synthesis [33,42]. PG contains
many D-alanyl-D-alanine residues to which vancomycin binds.
Therefore, thickened PG layers trap more vancomycin molecules
than the PG layers of normal thickness [43e45]. Moreover, the PG
mesh structure is clogged by the entrapped vancomycin, and serves
as an obstacle for further penetration of vancomycin to the cyto-
plasmic membrane where the real targets of vancomycin exist [46].
2) VRSA: cross-genus transmission of resistance gene.
Vancomycin MIC of VISA is 4e8 mg/L, which ‘was not’ consid-
ered resistant according to the CLSI criteria of the time. Therefore,
the word VISA was coined for Mu50 indicating its ‘intermediate’
level of vancomycin susceptibility. Five years later, in 2002, a VRSA
clinical strainwith MIC 16mg/L was isolated [47]. It turned out to
have acquired a vanA-transposon from vancomycin-resistant
Enterococcus (VRE). The transposon carried vanA-gene complex
containing vanA, vanH, vanX, and vanY. If the four genes function inconcert, all the D-Alanyl-D-Alanine residues of the substrate for PG
synthesis are replaced by D-Alanyl-D-lactate to which vancomycin
cannot bind. This amazing mechanism of resistance is described
elsewhere in detail [48]. In spite of the acquisition of this ingenious
system, however, so far only a dozen of VRSA clinical strains have
been reported in the world after more than a decade of its ﬁrst
isolation. The ﬁtness cost of the carriage of vanA plasmid was
suspected although growth retardation of the vanA plasmid-
carrying strain is reported to be minimum [49]. In fact, the vanA-
mediated vancomycin resistance is an inducible type, and does not
cause much ﬁtness cost during the growth in the absence of van-
comycin [70]. As an explanation for the unpopularity of the resis-
tance, we initially speculated that the level of methicillin resistance
might be much lowered due to the loss of D-Alanyl-D-Alanine
residues from the cell wall to which PBP2’ is supposed to bind.
However, we found that a VRSA clinical strain VRS1 simultaneously
expressed high-level resistance to both vancomycin and oxacillin
[70]. Therefore, the only remaining barrier for MRSA to acquire
vanA gene would be the availability of an efﬁcient mobile genetic
element carrying it. In this regard, a worrisome report on a trans-
missible vanA plasmid has been published [71]. Future prevalence
of VRSA is not an illusion as long as we continue using vancomycin
as the ﬁrst choice for MRSA infection. We have to develop new
chemotherapeutic agents against multi-resistant MRSA to prepare
for the future.
3) ‘sVISA’ e an ingenious strategy to survive vancomycin
chemotherapy
Vancomycin is still the ﬁrst-line antibiotic against MRSA infec-
tion. However, its clinical effectiveness is compromised even
against the strains whose vancomycin MICs are within the CLSI
susceptible range (2 mg/L) [50,51]. Also, the overall therapeutic
failure rates of vancomycin are too high to be explained by the
latent infection of VRSA (with vancomycin MIC of 16 mg/L) or
even of VISA (MIC  4 mg/L) [50,67e69]. It seems that many MRSA
strains exist whose vancomycin MIC values are in susceptible range
(2 mg/L), and yet ‘resisting’ vancomycin killing. hVISA is evidently
one of those strains resisting vancomycin by generating VISA at
high frequency. However, in this case, hVISA is converted to VISA
during the therapy, and the therapeutic failure is ascribed to the
VISA strain. In this case, VISA would be detected from clinical
specimen after vancomycin therapy. Using hVISA strain Mu3,
however, we noticed a transient VISA status designated ‘slow VISA
(sVISA)’ which returns to hVISA quickly once vancomycin is
removed from the culture [66]. This implies that hVISA infection
may not leave VISA after unsuccessful vancomycin therapy. Only
hVISA with susceptible levels of vancomycin MIC values would be
present after vancomycin therapy.
Fig. 4 illustrates the PA pattern of hVISA strain Mu3 evaluated
after 2 days (Mu3-48 h) and 6 days (Mu3-144 h) of incubation at
37 C. The usual PA test is evaluated after 2 days. However, when PA
was evaluated after 72 h (3 days) to 144 h (6 days) of incubation,
additional number of Mu3 colonies appeared on the BHI agar plates
containing 4 mg/L or greater concentrations of vancomycin (Fig. 2).
In contrast VSSA strain DIP did not generate additional colonies
after 48 h (Fig. 4). The number of the late-appearing colonies was
comparable to the number of the colonies that had appearedwithin
48 h of incubation. VISA is included within the latter group of
colonies, and sVISA was identiﬁed within the late-appearing col-
onies. The ﬁrst sVISA strain Mu3-6R-P (6R-P) was obtained in vitro
from hVISA strain Mu3 by the selection with 6 mg/L of vancomycin
[52].
6R-P grew extremely slowly, and did not draw our attention
until recently. Then its high level of vancomycin resistance was
Fig. 5. Vancomycin E-test of a representative sVISA strain. Pin-point colonies of sVISA
strain 12-5d were inoculated onto BHI agar plate, and E-test strip of vancomycin was
placed followed by incubation for 72 h. Highly frequent appearance of large colonies
was observed, which did not grow beyond the MIC level of 4 mg/L. On the other hand,
pin-point colonies, whose individual colonies are too small to be discriminated, grew
up to the level of MIC 16 mg/L.
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[66].) The strain 6R-P had a VISA phenotype similar to the extant
VISA strains; i.e., thickened cell wall and reduced autolytic activity.
However, it was distinct from extant VISA strains in its extremely
prolonged doubling time (DT) of 62.2 min, forming a pin-point
colony (PC) only after two days incubation on a drug-free agar
plate. The PA pattern of 6R-P is shown in Fig. 4. In contrast to Mu50,
6R-P does not form colonies on the agar plates containing 7mg/L or
greater concentrations of vancomycin within 48 h incubation,
whereas, it does after 72 he144 h of incubation (Fig. 4).
The most striking feature of 6R-P is the instability of VISA
phenotype. When passaged on drug-free agar plates, it generated
phenotypic revertants (PR) having larger colony sizes and signiﬁ-
cantly decreased vancomycin resistance. When 6R-P was passaged
in drug-freemedium, the culturewas quickly overgrown by PR cells
within several days. The appearance rate of PRs from 6R-P was
around 1 106 and was comparable to that of the emergence rate
of VISA from hVISA [52].
A total of 25 sVISA strains were obtained fromMu3 by selection
with 6 mg/L of vancomycin [66]. The colonies that appeared on the
vancmycin plates after 72 h (3 days) to 144 h (6 days) incubation at
37 C were picked, colony-puriﬁed, and established as sVISA
strains. Their vancomycin MICs increased with time of incubation,
while that of clinical VISA strains, represented by Mu50, did not
[66]. Some sVISA strains reached to the MIC values of 24 mg/L to
32 mg/L after 48e96 h incubation, whereas Mu50 remained at MIC
of 12 mg/L throughout the incubation time up to 144 h [66]. This
high MIC values of sVISA strains, however, were very unstable, and
PRs with large colony size, and decreased vancomycin resistance
appeared quickly in the drug-free culture. Some sVISA strains are
much more unstable than 6R-P, and generated large colonies with
reduced vancomycin resistance even within 72 h of incubation
(Fig. 5).
The biological feature of sVISA is intriguing. The sVISA status is
easily acquired by hVISA, and even by VSSA [66]. The sVISA
phenotype is a transient phenotype, but it can bemaintained stably
as long as it is passaged on the vancomycin-containing agar plates.
Thus, sVISA phenotype is likely to be maintained as long as van-
comycin therapy continues. When vancomycin treatment is lifted,
sVISA would quickly revert to hVISA without leaving the evidence
of VISA infection. This transient nature of resistance of sVISA may
explain at least a part of lower rate of VISA isolation than the
occurrence rate of the vancomycin-refractory MRSA infection.
4) RNAP regulatory mutation is a frequent mechanism for VISA
phenotype
RNAP mutation has been recognized as one of the major genetic
events raising VISA [33]. It was the case for sVISA as well. Thewhole
genome sequence determination of 6R-P revealed a single muta-
tion in rpoB gene encoding b subunit of RNAP [66]. The identiﬁed
mutation rpoB(R512P) was introduced into a VSSA laboratory strain
DIP by an allelic replacement method [66]. The resultant strain
DIPrpoB(R512P) possessed vancomycin MIC of 4 mg/L as compared
to 1 mg/L of DIP. The slow growth phenotype of sVISA was also
transferred to DIP, prolonging its DT from 26.7 to 41.2 min [66]. It
was remarkable that an rpoB mutation as a single agent conferred
VISA-level resistance (MIC, 4 mg/L) on even a VSSA strain. The daily
passage of 6R-P generated PRs at high frequency, and the culture
was 100% replaced by large colony-sized PRs by the 7th day of
passages. The four large colonies were picked from independent
experiments, and their rpoB genes were sequenced for the fate of
rpoB(R512P) mutation. Three out of the four large-colony variant
strains, 6R-P-L1, -L2, and -L3, possessed allelic nucleotide changes
in the 512th codon, replacing the Proline of Mu3-6R-P by Leucine,Serine and Histidine, respectively. Another sVISA strain 21-4d car-
rying rpoB(H929T) mutation had its rpoBmutation back mutated to
wild-type in three of the ﬁve PR strains tested. The sVISA strain 21-
4d produced large-colony PRs at an extremely high frequency of
5.4  105 after two-days drug-free passages [66]. The mechanism
for this high rate of mutations for phenotypic reversion is under
investigation.
A total of 25 sVISA strains were tested for their carriage of rpoB
mutations [66]. Seven (28%) strains possessed rpoB mutations. All
of them were located out of the rifampin-resistance determining
region (RRDR), and did not accompany rifampin resistance. In our
current on-going study, some mutations of another RNAP subunit
gene rpoC; i.e., rpoC(L418I) and rpoC(N744K) were found to confer
sVISA phenotype on hVISA strain Mu3 (Katayama, Y. in prepara-
tion). Therefore, sVISA phenotype seems to be expressed via the
alteration of the cell physiology brought about by the mutational
change in the structure and function of RNAP core enzyme. Besides
vancomycin, mutations in RNAP subunits are reported to affect
susceptibility of S. aureus to such antibiotics as b-lactam [53,54],
daptomycin [55e58], and linezolid [55]. Since RNAP is not the
direct target of action of any of these antibiotics, RNAP mutation
must be preventing the adverse effects of the antibiotics by
changing the physiological status of the cell signiﬁcantly. This
should accompany high ﬁtness cost for the cell, and is the cause for
the transient nature of the sVISA phenotype.
Finally, there are more number of sVISA strains having no mu-
tation in RNAP [66]. Whole genome sequencing of those sVISA
strains are on-going to identify the non-rpo gene mutations to
K. Hiramatsu et al. / J Infect Chemother 20 (2014) 593e601 599obtain a comprehensive view on the genetic basis for sVISA
phenotype.
3. Future chemotherapy for S. aureus infection
3.1. Nybomycin as a reverse antibiotic for quinolone resistance
S. aureus is a member of our natural ﬂora. About 20e30% of
humans have been reported to possess S. aureus in the anterior
nares. No trend of decline of S. aureus carriage by healthy in-
dividuals is noticed after 7 decades of use of man-made antibiotics.
This fact shows that S. aureus is so well tuned to human body and
would never be cleared off from their habitat how energetically we
develop new antibiotics with new targets of action. It is evident
from the history of chemotherapy in the last century that S. aureus
can develop resistance to any antibiotic. As seen in the old deri-
vation of mecA in the history of life on the earth, antibiotic resis-
tance is the natural consequence of the production of antibiotics.
Based on this principle, we should design a new chemotherapeutic
strategy. The bacteria of our time is drastically changed as
compared to that of the 1940s, whenmore than half of the hospital-
associated S. aureus is methicillin-resistant, and more than 80%
VISA are quinolone-resistant [59]. Given this, it is much more
promising to develop an antibiotic that has stronger activity against
the S. aureus strains resistant to extant antibiotics rather than
against wild-type S. aureus strains which are still susceptible to
them. If such anti-resistance antibiotics were used in combination
with the extant antibiotics, most of the S. aureus infections would
become treatable.
By screening 1928 culture supernatants of Actinobacteria, we
identiﬁed a curious substance that possessed a strong bactericidal
activity against ﬂuoroquinolone-resistant VISA strain Mu50,Fig. 6. Nybomycin binding to the Quinolone Pocket of the Gyrase A with its 84th Serine resi
the crystal structure of GyrB27-A56 (Tyr123Phe) reported by Bax BD et al. [63]. To reproduce
hydroxy group was modiﬁed to make a phosphoester bond connected to the 5' terminal o
using Bluto [64], with ciproﬂoxacin kept in the cavity. The docking calculation was perform
compounds other than ciproﬂoxacin. The values under the ﬁgures are calculated binding en
magnesium chelate and the hydrogen bond network surrounding it. The chelate is compos
nolone, and the side chains of Ser84 and Glu88 of DNA Gyrase subunit A. Abbreviation: wt, w
Serine replaced by Leucine by a point mutation, the hydrophobic side chain of the Leucin
stabilized. (C) Nybomycin is stabilized in the mutated quinolone pocket because of its hydro
docking mode was found with the combination of Nybomycin and wild-type gyrase.whereas only a weak activity against ﬂuoroquinolon-, and
methicillin-susceptible VSSA strain FDA209P [59]. The substance
was found out to be an old antibiotic Nybomycin (NYB) that had
been reported in 1955 [60]. We found that NYB strongly inhibited
the function of the mutated DNA gyrase of quinolone-resistant
Mu50, but did not inhibit the function of the wild-type DNA gyr-
ase of quinolone-susceptible S. aureus [59]. Docking simulation
study revealed stable binding of NYB to the quinolone-binding
pocket of the GyrA having gyrA(S84L) mutation (Fig. 6). On the
other hand, ﬂuoroquinolone antibiotics cannot bind to it due to the
mutational loss of the Serine residue, which is important to retain
hydrogen-bond network for the stabilization of quinolonemolecule
in the quinolone-binding pocket (Fig. 6).
3.2. Dissolving the vicious cycle between antibiotics and antibiotic
resistance
Bacteria always ﬁnd the way to develop resistance to any anti-
biotic. As is expected, NYB was not exempt from the emergence of
resistance, either. Mu50 did generate NYB-resistant mutants
(temporarily deﬁned by MIC  4 mg/L), although at extremely low
frequencies: the appearance rates were 0.663e15.3  1011 [59].
However, surprisingly, all of the nine independently obtained
resistant mutant strains were susceptible to ﬂuoroquinolone anti-
biotics [59]. Nucleotide sequencing revealed that their gyrA genes
of the resistant mutants were back mutated to the wild type.
Therefore the resistant mutants were genetic revertants [59].
Accordingly, we designated NYB as a ‘Reverse Antibiotic’ (RA)
against quinolone-resistant bacteria [59]. Recently, we found that
some of the ﬂavones as well are RAs against ﬂuoroquinolone-
resistant bacteria (Morimoto, Y. et al. in preparation). Flavones are
known as natural antibiotics produced by plants [61]. NYB is also adues replaced by Leucine. The quinolone binding site model was constructed based on
the cleaved state of DNA, the mutated Phenylalanine was corrected to Tyrosine and its
f DNA. The side chain conformation around the quinolone-binding site was optimized
ed according to Adam [65], with a docking grid expanded by 1.3 angstrom to accept
ergy. (A) The binding between GyrA and quinolone is stabilized through the octahedral
ed of the oxygen atoms of water, the carbonyl and carboxylic acid groups of the qui-
ild-type. (B) In the interaction between ﬂuoroquinolone and altered GyrA with its 84th
e does not support the formation of the hydrogen-bond network. The binding is not
phobic methyl side chain facing the hydrophobic side chain of 84th Leucine. No stable
Fig. 7. Resolving the problem of multi-drug resistance by the use of Reverse Antibi-
otics. The use of quinolone results in the emergence of quinolone-resistant strains with
mutated gyrA. Nybomycin is effective against the quinolone-resistant mutants. How-
ever, the use of Nybomycin generates Nybomycin-resistant mutants with their
mutated gyrA back (reverse) mutated to wild type. Therefore, quinolones regain ac-
tivity against the Nybomycin-resistant mutants. In this way, alternate use of Quinolone
and Nybomycin always keeps the bacteria susceptible to either one of the two anti-
biotics, and does not allow development of multi-drug resistance. Abbreviation: S,
susceptible; R, resistant. The structural formula of quinolone is that of Ciproﬂoxacin.
K. Hiramatsu et al. / J Infect Chemother 20 (2014) 593e601600natural antibiotic. Therefore, it is likely that there are rich reper-
toires of antibiotics and reverse antibiotics stored in nature. RAs
acting on other targets than topoisomerases such as mutated RNAP
may be found as well in nature. With reverse antibiotics as a
countermeasure for the rise of antibiotic-resistant bacteria, all the
living microorganisms co-existed on the earth by maintaining
natural homeostasis. Therefore, by developing RAs and using them
together with the extant antibiotics developed in the last century,
we would be able to control most of the multidrug-resistant bac-
terial infectionwithout trying in vain to reach the unattainable goal
of extinguishing the historically given our natural ﬂora (Fig. 7).4. Conclusion
The origin of mecA gene was traced back to S. ﬂeurettii chro-
mosome. Mutation of rpoB was found to play a major role in the
development of vancomycin resistance in S. aureus. Staphylococci
never stop evolving: it may acquire a highly efﬁcient plasmid car-
rying vanA gene in near future. We need to be vigilant on the
clinical MIC data of S. aureus, and have to be prepared for the future
by learning from the nature's ecosystem to control them without
trying to extinguish them. By using reverse antibiotics, many extant
antibiotics will regain their potency, and history of antimicrobial
chemotherapy started by the discoverymade by Alexander Fleming
will ﬁnally be completed.Acknowledgment
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